Combating multidrug-resistant Gram-negative bacterial infections

Expert Opinion on Investigational Drugs

Volumn 23, Issue 2, 2014, Pages 163-182

  Xu, Ze Qi ^a,c   Flavin, Michael T ^b   Flavin, John ^c  

^a SynChem GMP   (United States)

^b Advanced Life Sciences   (United States)

^c Flavin Ventures   (United States)

Author keywords

Alternative strategies; Antibiotics; Gram negative bacteria; Multidrug resistance

Indexed keywords

AMINO ACID; AMINO ACID TRANSFER RNA LIGASE; AMINOGLYCOSIDE; ANTIBODY; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE INHIBITOR; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR; POLYPEPTIDE ANTIBIOTIC AGENT; SIDEROMYCIN; SIDEROPHORE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

BACTERIAL MEMBRANE; GENOMICS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 84892386739     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.848853     Document Type: Review

References (127)

1. Infectious Diseases Society of America. The 10 x ¢20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50:1081-3
2. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the infectious diseases society of America. Clin Infect Dis 2009;48:1-12
3. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008;197:1079-81 (Pubitemid 351590040)
4. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 2009;360:439-43
5. Taubes G. The bacteria fight back. Science 2008;321:356-61
6. Torres C. Up against wall. Nat Med 2010;16:628-31
7. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011;24:71-109
8. Coates A, Hu Y, Bax R, Page C. The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov 2002;1:895-910 (Pubitemid 37361584)
9. Powers JH. Antimicrobial drug development-the past, the present, and the future. Clin Microbiol Infect 2004;10(Suppl 4):23-31
10. Bartlett JG, Barie PS, Niederman MS, Wunderink RG. Workshop on clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated pneumonia. Clin Infect Dis 2010;51(S1):S1-3
11. Novak R, Shlaes DM. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs 2010;11:182-91
12. Venugopal AA, Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 2012;54:568-74
13. Giske CD, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant Gramnegative bacilli. Antimicrob Agents Chemother 2008;52:813-21 (Pubitemid 351358357)
14. Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother 2011;66(Suppl 3):iii11-18
15. Pan X, Wang P, Hu N, et al. A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline/antofloxacin interaction in both rats and humans. Drug Metab Pharmacokinet 2011;26:387-98
16. Chahine EB, Ferrill MJ, Poulakos MN. Doripenem: a new carbapenem antibiotic. Am J Health Syst Pharm 2010;67:2015-24
17. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010;51:1238-44
18. Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2010;53:1898-916
19. Coates ARM, Halls G, Hu Y. Novel classes of antibiotics or more of the same Br J Pharmacol 2011;163:184-94
20. Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-time to react is now. Drug Resist Updat 2011;14:118-24
21. Bush K. Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol 2010;13:558-64
22. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011;55:4943-60
23. Kuroki H, Tateno N, Ikeda H, Saito N. Investigation of pneumonia-causing pathogenic organisms in children and the usefulness of tebipenem pivoxil for their treatment. J Infect Chemother 2010;16:280-7
24. Hirai Y, Takahata S, Yamada K, et al. Correlation of the antimicrobial activity of ME1036 with its binding affinities to the penicillin-binding proteins from Streptococcus pneumoniae strains. J Antibiot 2011;64:741-6
25. Sader HS, Gales AC. Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents. Drugs 2001;61:553-64 (Pubitemid 32453367)
26. Bulik CC, Tessier PR, Keel RA, et al. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse Gram-negative organisms. Antimicrob Agents Chemother 2012;56:544-9
27. Titelman E, Karlsson IM, Ge Y, Giske CG. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14-and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011;70:137-41
28. Bebrone C, Lassaux P, Vercheval L, et al. Current challenges in antimicrobial chemotherapy. Focus on beta-lactamase inhibition. Drugs 2010;70:651-79
29. Ruzin A, Petersen PJ, Jones CH. Resistance development profiling of piperacillin in combination with the novel beta-lactamase inhibitor BLI-489. J Antimicrob Chemother 2010;65:252-7
30. Jamieson CE, Lambert PA, Simpson IN. In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother 2003;47:2615-18 (Pubitemid 36919467)
31. Bowker KE, Noel AR, Walsh TR, et al. Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta-lactamases. Antimicrob Agents Chemother 2004;48:4482-4 (Pubitemid 39434924)
32. Paukner S, Hesse L, Prezelj A, et al. In vitro activity of LK157, a novel tricyclic carbapenem as broad-spectrum beta-lactamase inhibitor. Antimicrob Agents Chemother 2009;53:505-11
33. Plantan I, Selic L, Mesar T, et al. 4-Substituted trinems as broad spectrum beta-lactamase inhibitors: structure-based design, synthesis, and biological activity. J Med Chem 2007;50:4113-21 (Pubitemid 47301743)
34. Iglicar P, Legen I, Vilfan G, et al. Permeability of a novel beta-lactamase inhibitor LK-157 and its ester prodrugs across rat jejunum in vitro. J Pharm Pharmacol 2009;61:1211-18
35. Ehmann DE, Jahić H, Ross PL, et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci USA 2012;109:11663-8
36. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012;39:86-9
37. Louie A, Castanheira M, Liu W, et al. Pharmacodynamics of beta-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of beta-lactamases. Antimicrob Agents Chemother 2012;56:258-70
38. Lagacé-Wiens PR, Tailor F, Simner P, et al. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother 2011;55:2434-7
39. Livermore DM, Mushtaq S, Barker K, et al. Characterization of beta-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J Antimicrob Chemother 2012;67:1354-8
40. Levasseur P, Girard AM, Claudon M, et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2012;56:1606-8
41. Mangion IK, Ruck RT, Rivera N, et al. A concise synthesis of a beta-lactamase inhibitor. Org Lett 2011;13:5480-3
42. Hirsch EB, Ledesma KR, Chang KT, et al. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 2012;56:3753-7
43. Bhagunde P, Chang KT, Hirsch EB, et al. Novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors. Antimicrob Agents Chemother 2012;56:2237-40
44. Livermore DM, Mushtaq S, Morinaka A, et al. Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes. J Antimicrob Chemother 2013;68:153-8
45. Ishii Y, Eto M, Mano Y, et al. In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta- lactamaseproducing Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2010;54:3625-9
46. Shlaes DM. New beta-lactam-beta-lactamase inhibitor combinations in clinical development. Ann NY Acad Sci 2013;1277:105-14
47. Yang L, Ye X-S. Development of aminoglycoside antibiotics effective against resistant bacterial strains. Curr Top Med Chem 2010;10:1898-926
48. Armstrong ES, Miller GH. Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr Opin Microbiol 2010;13:565-73
49. Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 2012;10:459-73
50. Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 2011;66:48-53
51. Galani I, Souli M, Daikos GL, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother 2012;24:191-4
52. Xiao XY, Hunt DK, Zhou J, et al. Fluorocyclines. 1. 7-fluoro-9- pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 2012;55:597-605
53. Grossman TH, Starosta AL, Fyfe C, et al. Target-and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 2012;56:2559-64
54. Fleischmann RD, Adams MD, White O, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995;269:496-512
55. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6:29-40 (Pubitemid 46020284)
56. Seiradake E, Mao W, Hernandez V, et al. Crystal structures of the human and fungal cytosolic leucyl-tRNA synthetase editing domains: a structural basis for the rational design of antifungal benzoxaboroles. J Mol Biol 2009;390:196-207
57. Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase bymtrapping tRNA in the editing site. Science 2007;316:1759-61 (Pubitemid 46988553)
58. Butler MS, Cooper MA. Antibiotics in the clinical pipeline in 2011. J Antibiotics 2011;64:413-25
59. Guay DRP. Drug forecast-the peptide deformylase inhibitors as antibacterial agents. Ther Clin Risk Manag 2007;3:513-25 (Pubitemid 47496955)
60. Chen DZ, Patel DV, Hackbarth CJ, et al. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 2000;39:1256-62 (Pubitemid 30090692)
61. Yoo JS, Zheng CJ, Lee S, et al. Macrolactin N, a new peptide deformylase inhibitor produced by Bacillus subtilis. Bioorg Med Chem Lett 2006;16:4889-92 (Pubitemid 44202589)
62. Ramanathan-Girish S, McColm J, Clements JM, et al. Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob Agents Chemother 2004;48:4835-42 (Pubitemid 39577691)
63. Naderer OJ, Dumont E, Zhu J, et al. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother 2013;57:2005-9
64. Rolan P, Sun H, Macleod C, et al. Pharmacokinetics and unexpected safety issues of LBM415, a novel oral peptide deformylase inhibitor. Clin Pharmacol Ther 2011;90:256-62
65. Naderer OJ, Dumont E, Zhu J, et al. Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebo-controlled study. J Antimicrob Chemother 2013;68:1901-9
66. Mamelli L, Petit S, Chevalier J, et al. New antibiotic molecules: bypassing the membrane barrier of Gram-negative bacteria increases the activity of peptide deformylase inhibitors. PLoS One 2009;4:e6443
67. Hadley EB, Hancock REW. Strategies for the discovery and advancement of novel cationic antimicrobial peptides. Curr Top Med Chem 2010;10:1872-81
68. Findlay B, Zhanel GG, Schweizer F. Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold. Antimicrob Agents Chemother 2010;54:4049-58
69. Wimley WC. Describing the mechanism of antimicrobial peptide action with the interfacial activity model. ACS Chem Biol 2010;5:905-17
70. Baltzer SA, Brown MH. Antimicrobial peptides: promising alternatives to conventional antibiotics. J Mol Microbiol Biotechnol 2011;20:228-35
71. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis 2008;47:1537-45
72. Melo MN, Dugourd D, Castanho MA. Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides. Recent Pat Antiinfect Drug Discov 2006;1:201-7
73. Rubinchik E, Dugourd D, Algara1 T, et al. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Chemother 2009;34:457-61
74. Gruenheid S, Le Moual H. Resistance to antimicrobial peptides in Gram-negative bacteria. FEMS Microbiol Lett 2012;330:81-9
75. Fjell CD, Hiss JA, Hancock RE, Schneider G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 2012;11:37-51
76. Hu J, Chen C, Zhang S, et al. Designed antimicrobial and antitumor peptides with high selectivity. Biomacromolecules 2011;12:3839-43
77. Bommarius B, Jenssen H, Elliott M, et al. Cost-effective expression and purification of antimicrobial and host defense peptides in Escherichia coli. Peptides 2010;31:1957-65
78. Tew GN, Scott RW, Klein ML, Degrado WF. De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications. Acc Chem Res 2010;43:30-9
79. Giuliani A, Rinaldi AC. Beyond natural antimicrobial peptides: multimeric peptides and other peptidomimetic approaches. Cell Mol Life Sci 2011;68:2255-66
80. Thaker HD, Sgolastra F, Clements D, et al. Synthetic mimics of antimicrobial peptides from triaryl scaffolds. J Med Chem 2011;54:2241-54
81. Yang L, Gordon VD, Mishra A, et al. Synthetic antimicrobial oligomers induce a composition-dependent topological transition in membranes. J Am Chem Soc 2007;129:12141-7 (Pubitemid 47556850)
82. Isaksson J, Brandsdal BO, Engqvist M, et al. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem 2011;54:5786-95
83. Saravolatz LD, Pawlak J, Johnson L, et al. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus. Antimicrob Agents Chemother 2012;56:4478-82
84. Foley TL, Simeonov A. Targeting iron assimilation to develop new antibacterials. Expert Opin Drug Discov 2012;7:831-47
85. Kelly RJ, Giaccone G. The role of talactoferrin a in the treatment of non-small cell lung cancer. Expert Opin Biol Ther 2010;10:1379-86
86. Venkatesh MP, Rong L. Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative staphylococci and Candida albicans causing neonatal sepsis. J Med Microbiol 2008;57(Pt 9):1113-21
87. van der Does AM, Bogaards SJ, Ravensbergen B, et al. Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colonystimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrob Agents Chemother 2010;54:811-16
88. van der Does AM, Hensbergen PJ, Bogaards SJ, et al. The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity. J Immunol 2012;188:5012-19
89. Velden WJ, van Iersel TM, Blijlevens NM, Donnelly JP. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med 2009;7:44
90. Braun V, Pramanik A, Gwinner T, et al. Sideromycins: tools and antibiotics. Biometals 2009;22:3-13
91. Page MGP. Siderophore conjugates. Ann NY Acad Sci 2013;1277:115-26
92. Rigel NW, Silhavy TJ. Making a betabarrel: assembly of outer membrane proteins in Gram-negative bacteria. Curr Opin Microbiol 2012;15:189-93
93. Livermore DM, Mushtaq S, Warner M. Activity of BAL30376 (monobactam BAL197641+BAL29880+clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J Antimicrob Chemother 2010;65:2382-95
94. Higgins PG, Stefanik D, Page MG, et al. In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-nonsusceptible Acinetobacter baumannii. J Antimicrob Chemother 2012;67:1167-9
95. Page MG, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. Antimicrob Agents Chemother 2010;54:2291-302
96. Mushtaq S, Warner M, Livermore D. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J Antimicrob Chemother 2010;65:266-70
97. Ji C, Miller PA, Miller MJ. Iron transport-mediated drug delivery: practical syntheses and in vitro antibacterial studies of tris-catecholate siderophore-aminopenicillin conjugates reveals selectively potent antipseudomonal activity. J Am Chem Soc 2012;134:9898-901
98. Ji C, Miller MJ. Chemical syntheses and in vitro antibacterial activity of two desferrioxamine B-ciprofloxacin conjugates with potential esterase and phosphatase triggered drug release linkers. Bioorg Med Chem 2012;20:3828-36
99. Wencewicz TA, Long TE, Mollmann U, Miller MJ. Trihydroxamate siderophore-fluoroquinolone conjugates are selective sideromycin antibiotics that target Staphylococcus aureus. Conjugate Chem 2013;24:473-86
100. Nikaido H, Pagès J-M. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 2012;36:340-63
101. Schweizer HP. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery. Expert Opin Drug Discov 2012;7:633-42
102. Yoshida K, Nakayama K, Ohtsuka M, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg Med Chem 2007;15:7087-97 (Pubitemid 47451787)
103. Schumacher A, Trittler R, Bohnert JA, et al. Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. J Antimicrob Chemother 2007;59:1261-4 (Pubitemid 47073344)
104. Coban AY, Guney AK, Tanriverdi Cayci Y, Durupinar B. Effect of 1-(1-Naphtylmethyl)-piperazine, an efflux pump inhibitor, on antimicrobial drug susceptibilities of clinical Acinetobacter baumannii isolates. Curr Microbiol 2011;62:508-11
105. Chevalier J, Mahamoud A, Baitiche M, et al. Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in Enterobacter aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant strains. Int J Antimicrob Agents 2010;36:164-8
106. Mahamoud A, Chevalier J, Baitiche M, et al. An alkylaminoquinazoline restores antibiotic activity in Gram-negative resistant isolates. Microbiology 2011;157:566-71
107. Zeng B, Wang H, Zou L, et al. Evaluation and target validation of indole derivatives as inhibitors of the AcrAB-TolC efflux pump. Biosci Biotechnol Biochem 2010;74:2237-41
108. Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ. Waltzing transporters and 'the dance macabre' between humans and bacteria. Nat Rev Drug Discov 2007;6:56-65 (Pubitemid 46020286)
109. Oleksiewicz MB, Nagy G, Nagy E. Antibacterial monoclonal antibodies: back to the future Arch Biochem Biophys 2012;526:124-31
110. Ter Meulen J. Monoclonal antibodies in infectious diseases: clinical pipeline in 2011. Infect Dis Clin North Am 2011;25:789-802
111. Lu Q, Rouby JJ, Laterre PF, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother 2011;66:1110-16
112. François B, Luyt CE, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2012;40:2320-6
113. Amara N, Krom BP, Kaufmann GF, Meijler MM. Macromolecular inhibition of quorum sensing: enzymes, antibodies, and beyond. Chem Rev 2011;111:195-208
114. López EL, Contrini MM, Glatstein E, et al. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother 2010;54:239-43
115. Roux D, Pier GB, Skurnik D. Magic bullets for the 21st century: the reemergence of immunotherapy for multi-and pan-resistant microbes. J Antimicrob Chemother 2012;67:2785-7
116. Skurnik D, Davis MR Jr, Benedetti D, et al. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis 2012;205:1709-18
117. Livermore DM, Tulkens PM. Temocillin revived. J Antimicrob Chemother 2009;63:243-5
118. Hartl R, Widhalm S, Kerschner H, Apfalter P. Temocillin and meropenem to discriminate resistance mechanisms leading to decreased carbapenem susceptibility with focus on OXA-48 in Enterobacteriaceae. Clin Microbiol Infect 2013;19:E230-2
119. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011;15:e732-9
120. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 2012;67:255-68
121. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 2013;4(8):1-10
122. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol 2013;8:769-83
123. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 2012;25:450-70
124. Kollef MH, Golan Y, Micek ST, et al. Appraising contemporary strategies to combat multidrug resistant Gram-negative bacterial infections-proceedings and data from the Gram-negative resistance summit. Clin Infect Dis 2011;53(S2):S33-55
125. So AD, Gupta N, Brahmachari SK, et al. Towards new business models for R&D for novel antibiotics. Drug Resist Updat 2011;14:88-94
126. Ambrose PG. Antibiotic bill doesn't GAIN enough ground. Nat Med 2011;17:772
127. Xu ZQ, Xu ZY. Acta Pharm Sin. ( ) 2013;48:993-1004. (Chinese